27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- NextCure Inc (NASDAQ:NXTC) and LegoChem Biosciences Inc announced a collaboration and co-development agreement to generate a B7-H4 antibody-drug conjugate (ADC) and options for two additional targets.
- The B7-H4 ADC will utilize NextCure's B7-H4 antibody and LCB's ConjuAllTM ADC technology.
- Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products.
- Related: NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings.
- The parties will utilize their respective product development capabilities to generate the B7-H4 ADC and advance it to the clinic.
- In addition, there are options for the parties to nominate two additional targets for ADC development beyond B7-H4.
- "We are excited to work with LCB and apply ConjuAllTM, a leading ADC technology, to add a new treatment modality to our B7-H4 program," said Timothy Mayer, NextCure's Chief Operating Officer.
- Price Action: NXTC shares closed lower by 1.78% at $1.66 on Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!